SCHEMBL2179959

SCHEMBL2179959

O=S(=O)(c1cccc2cccnc12)N1CC2C(CNc3ccc(N4CCOCC4)c(F)c3)C2C1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.52
MAPK1 P28482 2/20 0.45
USP2 O75604 2/20 0.45
PKM P14618 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
MAPT P10636 1/20 0.44
TSHR P16473 2/20 0.43
GFER P55789 1/20 0.43
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
ALDH1A1 P00352 5/20 0.43
GAA P10253 3/20 0.43
TP53 P04637 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
KCNT2 Q6UVM3 1/20 0.41
ATM Q13315 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4412105 0.86 CHRM1 (0.45) SMN1; SMN2
SCHEMBL2179954 0.85 TP53 (0.53) L3MBTL1MAPK1USP2PKMNPSR1
SCHEMBL4423587 0.81 MEN1 (0.46) MAPK1PKMNPSR1MAPTTSHR
SCHEMBL2224122 0.80 SLC6A9 (0.45) L3MBTL1GAA
SCHEMBL4419968 0.79 L3MBTL1 (0.46) L3MBTL1MAPK1NPSR1ALDH1A1GAA
SCHEMBL4422791 0.79 NPC1 (0.40) L3MBTL1MAPK1MAPTTSHRALDH1A1
SCHEMBL4413651 0.78 NPC1 (0.42) L3MBTL1MAPK1USP2NPSR1MAPT
SCHEMBL4415660 0.78 ALDH1A1 (0.40) L3MBTL1MAPK1NPSR1TSHRALDH1A1
SCHEMBL4418890 0.78 MEN1 (0.47) L3MBTL1MAPK1NPSR1MAPTTSHR
SCHEMBL4414933 0.78 KMT2A (0.43) L3MBTL1MAPK1NPSR1MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP claimed
JP-4732354-B2 2011-07-27 JP claimed
EP-1680124-A4 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2009-05-13 EP claimed
JP-2007508374-A 2007-04-05 JP claimed
EP-1680124-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS Pfizer Products Incorporated (US) 2006-07-19 EP claimed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US claimed
WO-2005037216-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PRODUCTS INC. (US) 2005-04-28 WO claimed
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP disclosed
US-7473787-B2 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC (US) 2009-01-06 US disclosed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors SLC6A5, SLC1A5, SLC6A3 L3MBTL1 1416/4885MAPK1 2572/4885USP2 4830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.